Randomized trial · people
SS-31 (elamipretide) eye drops missed main vision goal in LHON trial
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In this small trial, elamipretide eye drops looked safe for people with LHON but did not improve sharpness of vision, and the hints of benefit on other vision tests still need confirming.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 12
- Published
- 2024
- Journal
- Ophthalmology
What they tested
The team tested whether elamipretide eye drops are safe in people with Leber hereditary optic neuropathy (LHON, an inherited condition that causes vision loss) and whether they improve vision.
How the study was done
A phase II, randomized, double-masked trial at 1 center in 12 adults aged 18 to 50 with a genetically confirmed form of LHON and vision loss lasting 1 to 10 years. For 52 weeks, people got elamipretide 1% drops in both eyes or in 1 eye with vehicle (drops without the drug) in the other, then all eyes got elamipretide in an open-label extension, where everyone knew the treatment, for up to 108 more weeks.

What they found
Elamipretide was well tolerated, most side effects were mild to moderate and went away on their own, and there were no serious side effects. Change in best-corrected visual acuity (sharpest vision with glasses or lenses) did not differ between elamipretide eyes and vehicle eyes at any time point, so the trial missed its main efficacy goal. Six of 12 people met the trial's criteria for a clinically relevant benefit. In a post hoc analysis, central visual field mean deviation improved more in elamipretide eyes than vehicle eyes, and color discrimination and contrast sensitivity improved from baseline during the open-label extension.
What it doesn’t show
This was a very small, single-center trial in 1 genetic form of LHON. The visual field result came from an analysis planned after the fact, and the gains in the open-label extension had no vehicle comparison.
The paper
Karanjia and Sadun Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial. Ophthalmology. 2024.
The compound
More studies on SS-31
- SS-31: wearable data grouped responders with 100% accuracyRandomized trial · people · 2023
- SS-31: no 12-week benefit, walk gains by 36 weeks open-labelRandomized trial · people · 2021
- SS-31 raised muscle ATP capacity after one dose in older adultsRandomized trial · people · 2021
- SS-31: walk distance rose with dose in 5-day MMPOWER trialRandomized trial · people · 2018
- SS-31: less kidney hypoxia after renal artery stenting in pilotRandomized trial · people · 2017
- SS-31 did not significantly cut infarct size in EMBRACE STEMIRandomized trial · people · 2016
- Every study on SS-31
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.